The discounts should be compared against the drugs’ “ultimate net price” rather than their indicated list price to gauge the ...

Analysts at Guggenheim Partners expect Voyxact to see “broad commercial uptake” given its relatively broad label compared ...

Tecvayli plus Darzalex led to an 83% boost to progression-free survival versus the current standard therapy in relapsed or ...

Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.

A coordinated national effort is emerging to bring alternatives to animal testing into routine preclinical use, backed by a ...

At one point in merger negotiations with Novartis, Avidity CEO Sarah Boyce and her team walked, cutting off access to a data ...

Novo Nordisk’s amycretin showed no weight-loss plateau over 36 weeks in patients with type 2 diabetes, suggesting its ...

Richard Pazdur, the new director of the Center for Drug Evaluation and Research, raised concerns amid the rollout of several ...

The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access ...

Previous mega blockbusters took years to reach their peak sales. Lilly’s tirzepatide franchise is on course to exceed them ...

Experts suggest the FDA’s Advanced Manufacturing Technologies designation could be a lifeline for improving production ...

Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau ...